Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients With EBV-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Trial Profile

Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients With EBV-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Epstein-Barr virus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Gastric cancer; Haemophagocytic lymphohistiocytosis; Leiomyosarcoma; Lymphoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder; Viraemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms EAP study
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 01 Nov 2017 According to an Atara Biotherapeutics media release, updated results will be presented at the ASH Annual Meeting in December 2017.
    • 01 Nov 2017 According to an Atara Biotherapeutics media release, Company's collaborating investigator, MSK Cancer Center will present the positive interim results (n=10) of the trial at the upcoming 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 10 Aug 2017 According to an Atara Biotherapeutics media release, multicenter data from this clinical study is expected to be presented at appropriate future scientific conferences.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top